Lazcluze FDA Approval History
FDA Approved: Yes (First approved August 20, 2024)
Brand name: Lazcluze
Generic name: lazertinib
Dosage form: Tablets
Company: Johnson & Johnson
Treatment for: Non Small Cell Lung Cancer
Lazcluze (lazertinib) is a kinase inhibitor used in combination with amivantamab for the treatment of EGFR-mutated non-small cell lung cancer.
- Lazcluze is indicated in combination with amivantamab for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.
Development timeline for Lazcluze
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
